Jean-Pascal Fournier1, Hui Yin1, Oriana Hoi Yun Yu1, Laurent Azoulay2. 1. Centre for Clinical Epidemiology (Fournier, Yin, Yu, Azoulay), Lady Davis Institute, Jewish General Hospital; Department of Epidemiology, Biostatistics and Occupational Health (Fournier), McGill University; Division of Endocrinology (Yu), Jewish General Hospital; Department of Oncology (Azoulay), McGill University, Montréal, Que. 2. Centre for Clinical Epidemiology (Fournier, Yin, Yu, Azoulay), Lady Davis Institute, Jewish General Hospital; Department of Epidemiology, Biostatistics and Occupational Health (Fournier), McGill University; Division of Endocrinology (Yu), Jewish General Hospital; Department of Oncology (Azoulay), McGill University, Montréal, Que. laurent.azoulay@mcgill.ca.
Abstract
BACKGROUND: Small cross-sectional studies have suggested that metformin, a first-line oral hypoglycemic agent, may lower thyroid-stimulating hormone (TSH) levels. Our objective was to determine whether the use of metformin monotherapy, when compared with sulfonylurea monotherapy, is associated with an increased risk of low TSH levels (<0.4 mIU/L) in patients with type 2 diabetes mellitus. METHODS: Using the Clinical Practice Research Datalink, we identified patients who began receiving metformin or sulfonylurea monotherapy between Jan. 1, 1988, and Dec. 31, 2012. We assembled 2 subcohorts of patients with treated hypothyroidism or euthyroidism, and followed them until Mar. 31, 2013. We used Cox proportional hazards models to evaluate the association of low TSH levels with metformin monotherapy, compared with sulfonylurea monotherapy, in each subcohort. RESULTS: A total of 5689 patients with treated hypothyroidism and 59,937 euthyroid patients were included in the subcohorts. Among patients with treated hypothyroidism, 495 events of low TSH levels were observed during follow-up (incidence rate 119.7/1000 person-years). In the euthyroid group, 322 events of low TSH levels were observed (incidence rate 4.5/1000 person-years). Compared with sulfonylurea monotherapy, metformin monotherapy was associated with a 55% increased risk of low TSH levels in patients with treated hypothyroidism (incidence rate 79.5/1000 person-years v. 125.2/1000 person-years, adjusted hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.09-2.20), with the highest risk in the 90-180 days after initiation (adjusted HR 2.30, 95% CI 1.00-5.29). No association was observed in euthyroid patients (adjusted HR 0.97, 95% CI 0.69-1.36). INTERPRETATION: In this longitudinal population-based study, metformin use was associated with an increased incidence of low TSH levels in patients with treated hypothyroidism, but not in euthyroid patients. The clinical consequences of this need further investigation.
BACKGROUND: Small cross-sectional studies have suggested that metformin, a first-line oral hypoglycemic agent, may lower thyroid-stimulating hormone (TSH) levels. Our objective was to determine whether the use of metformin monotherapy, when compared with sulfonylurea monotherapy, is associated with an increased risk of low TSH levels (<0.4 mIU/L) in patients with type 2 diabetes mellitus. METHODS: Using the Clinical Practice Research Datalink, we identified patients who began receiving metformin or sulfonylurea monotherapy between Jan. 1, 1988, and Dec. 31, 2012. We assembled 2 subcohorts of patients with treated hypothyroidism or euthyroidism, and followed them until Mar. 31, 2013. We used Cox proportional hazards models to evaluate the association of low TSH levels with metformin monotherapy, compared with sulfonylurea monotherapy, in each subcohort. RESULTS: A total of 5689 patients with treated hypothyroidism and 59,937 euthyroid patients were included in the subcohorts. Among patients with treated hypothyroidism, 495 events of low TSH levels were observed during follow-up (incidence rate 119.7/1000 person-years). In the euthyroid group, 322 events of low TSH levels were observed (incidence rate 4.5/1000 person-years). Compared with sulfonylurea monotherapy, metformin monotherapy was associated with a 55% increased risk of low TSH levels in patients with treated hypothyroidism (incidence rate 79.5/1000 person-years v. 125.2/1000 person-years, adjusted hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.09-2.20), with the highest risk in the 90-180 days after initiation (adjusted HR 2.30, 95% CI 1.00-5.29). No association was observed in euthyroid patients (adjusted HR 0.97, 95% CI 0.69-1.36). INTERPRETATION: In this longitudinal population-based study, metformin use was associated with an increased incidence of low TSH levels in patients with treated hypothyroidism, but not in euthyroid patients. The clinical consequences of this need further investigation.
Authors: Sebastian Schneeweiss; Amanda R Patrick; Til Stürmer; M Alan Brookhart; Jerry Avorn; Malcolm Maclure; Kenneth J Rothman; Robert J Glynn Journal: Med Care Date: 2007-10 Impact factor: 2.983
Authors: Carlo Cappelli; Mario Rotondi; Ilenia Pirola; Barbara Agosti; Ana Maria Formenti; Pasquales De Cata; Massimo Salvetti; Luca Chiovato; Maurizio Castellano Journal: Hormones (Athens) Date: 2014 Apr-Jun Impact factor: 2.885
Authors: Miguel López; Luis Varela; María J Vázquez; Sergio Rodríguez-Cuenca; Carmen R González; Vidya R Velagapudi; Donald A Morgan; Erik Schoenmakers; Khristofor Agassandian; Ricardo Lage; Pablo Blanco Martínez de Morentin; Sulay Tovar; Rubén Nogueiras; David Carling; Christopher Lelliott; Rosalía Gallego; Matej Oresic; Krishna Chatterjee; Asish K Saha; Kamal Rahmouni; Carlos Diéguez; Antonio Vidal-Puig Journal: Nat Med Date: 2010-08-29 Impact factor: 53.440
Authors: D M Nathan; J B Buse; M B Davidson; E Ferrannini; R R Holman; R Sherwin; B Zinman Journal: Diabetologia Date: 2008-10-22 Impact factor: 10.122
Authors: Carlo Cappelli; Mario Rotondi; Ilenia Pirola; Barbara Agosti; Elena Gandossi; Umberto Valentini; Elvira De Martino; Antonio Cimino; Luca Chiovato; Enrico Agabiti-Rosei; Maurizio Castellano Journal: Diabetes Care Date: 2009-06-05 Impact factor: 19.112
Authors: Andreas Breit; Kristina Wicht; Ingrid Boekhoff; Evi Glas; Lisa Lauffer; Harald Mückter; Thomas Gudermann Journal: Mol Endocrinol Date: 2016-05-04